Chimeric seizes the day
Commandment Two: Don’t wasteth a successful trial result: go-eth to the well.
True to that lore, Chimeric Therapeutics (ASX:CHM) on Friday requested a trading halt “pending an announcement in relation to a capital raising”.
The shares are frozen until tomorrow, or possibly today if the news come through.
On Thursday Chimeric shares soared 60%, or two-thirds of the cents after the company said two out of three evaluable patients in its phase IIb trial had achieved a complete response.
A complete response means remission or – in layman’s terms – a cure.
The third patient had “achieved stable disease, whereby the cancer is neither increasing nor decreasing in extent or severity”.
The study tested Chimeric’s natural killer (NK) cells, agents in the blood stream with heightened cancer busting powers.
Chimeric’s candidate, CHM-0201 was administered alongside standard-of-care chemotherapy patients to the for acute myeloid leukemia.
The three patients are the first to be targeted of 20 subjects, with 12 enrolled as of December.
The first patient was dosed in June last year.
The three patients were ineligible for transplantation and had not been previously treated.
From a newsletter this evening
Add to My Watchlist
What is My Watchlist?
